Let’s look at the key reasons that are pushing Kymera Therapeutics Inc (KYMR) to new highs

Kymera Therapeutics Inc (NASDAQ: KYMR) on Friday, soared 7.68% from the previous trading day, before settling in for the closing price of $22.40. Within the past 52 weeks, KYMR’s price has moved between $19.44 and $53.27.

During the last 5-year period, the sales growth of Healthcare Sector giant was 233.20%. The company achieved an average annual earnings per share of -24.05%. With a float of $53.88 million, this company’s outstanding shares have now reached $64.89 million.

Let’s determine the extent of company efficiency that accounts for 188 employees. In terms of profitability, gross margin is 88.53%, operating margin of -545.36%, and the pretax margin is -475.57%.

Kymera Therapeutics Inc (KYMR) Breakdown of a Key Holders of the stock

Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Kymera Therapeutics Inc is 17.03%, while institutional ownership is 95.08%. The most recent insider transaction that took place on Mar 03 ’25, was worth 68,239. In this transaction Chief Legal Officer of this company sold 2,241 shares at a rate of $30.45, taking the stock ownership to the 80,085 shares. Before that another transaction happened on Mar 03 ’25, when Company’s Chief Operating Officer sold 1,383 for $30.45, making the entire transaction worth $42,113. This insider now owns 67,800 shares in total.

Kymera Therapeutics Inc (KYMR) Recent Fiscal highlights

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.93 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -24.05% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.89% during the next five years compared to -26.36% drop over the previous five years of trading.

Kymera Therapeutics Inc (NASDAQ: KYMR) Trading Performance Indicators

Kymera Therapeutics Inc (KYMR) is currently performing well based on its current performance indicators. A quick ratio of 7.53 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 33.28.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.97, a number that is poised to hit -0.91 in the next quarter and is forecasted to reach -4.12 in one year’s time.

Technical Analysis of Kymera Therapeutics Inc (KYMR)

Looking closely at Kymera Therapeutics Inc (NASDAQ: KYMR), its last 5-days average volume was 1.35 million, which is a jump from its year-to-date volume of 0.67 million. As of the previous 9 days, the stock’s Stochastic %D was 43.98%. Additionally, its Average True Range was 2.62.

During the past 100 days, Kymera Therapeutics Inc’s (KYMR) raw stochastic average was set at 15.65%, which indicates a significant decrease from 31.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 100.69% in the past 14 days, which was higher than the 69.39% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $32.32, while its 200-day Moving Average is $41.02. However, in the short run, Kymera Therapeutics Inc’s stock first resistance to watch stands at $25.35. Second resistance stands at $26.58. The third major resistance level sits at $28.23. If the price goes on to break the first support level at $22.47, it is likely to go to the next support level at $20.82. Now, if the price goes above the second support level, the third support stands at $19.59.

Kymera Therapeutics Inc (NASDAQ: KYMR) Key Stats

Market capitalization of the company is 1.57 billion based on 64,944K outstanding shares. Right now, sales total 47,070 K and income totals -223,860 K. The company made 7,390 K in profit during its latest quarter, and -70,750 K in sales during its previous quarter.